The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Multiple sclerosis
Abstract
Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurological disability in young adults. As with all complex traits, the disorder results from an interplay between as yet unidentified environmental factors and susceptibility genes. Together, these factors trigger a cascade of events, involving engagement of the immune system, acute inflammatory injury of axons and glia, recovery of function and structural repair, post-inflammatory gliosis, and neurodegeneration. The sequential involvement of these processes underlies the clinical course characterised by episodes with recovery, episodes leaving persistent deficits, and secondary progression. The aim of treatment is to reduce the frequency, and limit the lasting effects, of relapses, relieve symptoms, prevent disability arising from disease progression, and promote tissue repair. Despite limited success in each of these categories, everyone touched by multiple sclerosis looks for a better dividend from applying an improved understanding of the pathogenesis to clinical management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390501 · Cited by 1,559
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Beck, R. W., Cleary, P. A., Anderson, M. M., Keltner, J. L., Shults, W. T., Kaufman, D. I., Buckley, E. G., Corbett, J. J., Kupersmith, M. J., Miller, N. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260901 · Cited by 1,355
Research works printed but not linked: 7
- Homes, 1995, The cost of multiple sclerosis, Br J Med Econ, 18, 181
- Sawcer S, Meranian M, Setakis E, et al. A whole genome screen for linkage disequilibirum in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain (in press).
- Sriram, 1999, Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis, Ann Neurol, 46, 6, 10.1002/1531-8249(199907)46:1<6::AID-ANA4>3.0.CO;2-M · doi:10.1002/1531-8249(199907)46:1<6::aid-ana4>3.0.co;2-m
- Panitch, 1997, Clinical trials of a phase III trial of oral myelin in replacing-remitting multiple sclerosis, Ann Neurol, 42, 459
- 2000, Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial, Neurology, 54, 2352
- Coles, 1999, Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis, Ann Neurol, 46, 296, 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-# · doi:10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#
- Lucchinetti, 2000, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol, 47, 707, 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q · DOI
Cited by
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Metadata
- Authors
- Compston, A., & Coles, A.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Compston, Alastair
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 359
- Issue
- 9313
- Pages
- 1221-1231
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4241890711
- Cited by
- 1,743
- References
- 78
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 45 · 2023: 44 · 2022: 61 · 2021: 80 · 2020: 87 · 2019: 68 · 2018: 78 · 2017: 92 · 2016: 106 · 2015: 94 · 2014: 101 · 2013: 92 · 2012: 105
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, autoimmune disease, neuroinflammation, environmental risk factors, genetic susceptibility, immune activation, axonal injury, neurodegeneration, relapse, disability progression, disease-modifying therapy, tissue repair
- MeSH terms
- Adult, Clinical Trials as Topic, Environment, Female, Humans, Male, Multiple Sclerosis, Risk Factors, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple sclerosis. https://app.cochat.ai/papers/10.1016/s0140-6736(02)08220-x
- The paper
- Compston, A., & Coles, A. (2002). Multiple sclerosis. The Lancet. https://doi.org/10.1016/s0140-6736(02)08220-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.